Abstract
Purpose of review Despite the high cure rate of germ-cell tumors (GCTs), the 5-year survival rate for those patients with metastatic poor-risk GCT rarely exceeds 50%. The purpose of this review is to highlight past and recent discoveries in the treatment of patients with poor-risk GCT. Recent findings Multiple clinical trials to optimize the management of poor-risk germ-cell cancer are ongoing. First-line phase II clinical trials of dose-dense multidrug and paclitaxel-based regimens such as accelerated bleomycin, etoposide, and cisplatin (BEP), dose-dense chemotherapy and paclitaxel, ifosfamide, and cisplatin (TIP) reported promising results. Positive phase III data are still lacking. Summary Four cycles of BEP or Etoposide (VP16), ifosfamide, cisplatin (VIP) continue to be the standard of care in patients with poor-risk GCT. A significant disparity in patient outcome exists between high-volume and low-volume centers. Referral for centers of excellence should be considered in the management of poor-risk GCT.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 474-478 |
| Number of pages | 5 |
| Journal | Current Opinion in Urology |
| Volume | 28 |
| Issue number | 5 |
| DOIs | |
| State | Published - Jan 1 2018 |
Fingerprint
Keywords
- Cisplatin
- Germ-cell tumor
- International Germ Cell Consensus Classification Group
- Poor-risk
- Primary mediastinal nonseminoma
ASJC Scopus subject areas
- Urology
Cite this
Current medical management of patients with poor-risk metastatic germ-cell tumors. / Albany, Costantine.
In: Current Opinion in Urology, Vol. 28, No. 5, 01.01.2018, p. 474-478.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Current medical management of patients with poor-risk metastatic germ-cell tumors
AU - Albany, Costantine
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Purpose of review Despite the high cure rate of germ-cell tumors (GCTs), the 5-year survival rate for those patients with metastatic poor-risk GCT rarely exceeds 50%. The purpose of this review is to highlight past and recent discoveries in the treatment of patients with poor-risk GCT. Recent findings Multiple clinical trials to optimize the management of poor-risk germ-cell cancer are ongoing. First-line phase II clinical trials of dose-dense multidrug and paclitaxel-based regimens such as accelerated bleomycin, etoposide, and cisplatin (BEP), dose-dense chemotherapy and paclitaxel, ifosfamide, and cisplatin (TIP) reported promising results. Positive phase III data are still lacking. Summary Four cycles of BEP or Etoposide (VP16), ifosfamide, cisplatin (VIP) continue to be the standard of care in patients with poor-risk GCT. A significant disparity in patient outcome exists between high-volume and low-volume centers. Referral for centers of excellence should be considered in the management of poor-risk GCT.
AB - Purpose of review Despite the high cure rate of germ-cell tumors (GCTs), the 5-year survival rate for those patients with metastatic poor-risk GCT rarely exceeds 50%. The purpose of this review is to highlight past and recent discoveries in the treatment of patients with poor-risk GCT. Recent findings Multiple clinical trials to optimize the management of poor-risk germ-cell cancer are ongoing. First-line phase II clinical trials of dose-dense multidrug and paclitaxel-based regimens such as accelerated bleomycin, etoposide, and cisplatin (BEP), dose-dense chemotherapy and paclitaxel, ifosfamide, and cisplatin (TIP) reported promising results. Positive phase III data are still lacking. Summary Four cycles of BEP or Etoposide (VP16), ifosfamide, cisplatin (VIP) continue to be the standard of care in patients with poor-risk GCT. A significant disparity in patient outcome exists between high-volume and low-volume centers. Referral for centers of excellence should be considered in the management of poor-risk GCT.
KW - Cisplatin
KW - Germ-cell tumor
KW - International Germ Cell Consensus Classification Group
KW - Poor-risk
KW - Primary mediastinal nonseminoma
UR - http://www.scopus.com/inward/record.url?scp=85056562507&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056562507&partnerID=8YFLogxK
U2 - 10.1097/MOU.0000000000000529
DO - 10.1097/MOU.0000000000000529
M3 - Review article
C2 - 29979236
AN - SCOPUS:85056562507
VL - 28
SP - 474
EP - 478
JO - Current Opinion in Urology
JF - Current Opinion in Urology
SN - 0963-0643
IS - 5
ER -